Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / BLRX - biolinerx GAAP EPS of -$0.04 beats by $0.42

BLRX - biolinerx GAAP EPS of -$0.04 beats by $0.42

BioLineRx Ltd.
biolinerx press release (NASDAQ:BLRX): FY GAAP EPS of -$0.04 beats by $0.42. CEO comment: "With over $57 million in cash, we believe we are well financed to extract maximum value from Motixafortide in SCM while at the same time advancing our other pipeline programs." Upcoming Expected Milestones: Submission of NDA to FDA for Motixafortide as novel mobilization agent for multiple myeloma patients undergoing autologous stem cell transplantation in mid-2022; Announce initial results for Part 2 of Phase 1/2a trial of AGI-134 in solid tumors in H2 2022; Initiate Phase 2 study of AGI-134 in 2023; Potential FDA approval of Motixafortide in 2023; Potential US launch of Motixafortide in SCM in 2023.

For further details see:

biolinerx GAAP EPS of -$0.04 beats by $0.42
Stock Information
Company Name: BioLineRx Ltd.
Stock Symbol: BLRX
Market: NASDAQ
Website: biolinerx.com
Menu
BLRX BLRX Quote BLRX Short BLRX News BLRX Articles BLRX Message Board
Get BLRX Alerts

News, Short Squeeze, Breakout and More Instantly...